What is the present valuation and projected CAGR of the invasive fungal infections market?
The invasive fungal infections market size has grown steadily in recent years. It will grow from $7.58 billion in 2024 to $7.96 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to global spread of infections, hematopoietic stem cell transplants, aging population, hospital-acquired infections, environmental factors.
The invasive fungal infections market size is expected to see steady growth in the next few years. It will grow to $9.6 billion in 2029 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to global health preparedness, public health education, novel antifungal agents, climate change impact, multidisciplinary approaches. Major trends in the forecast period include advancements in diagnostic technologies, tailored therapeutic approaches, patient-centric care, combination antifungal therapies, collaborations for drug development.
Get Your Free Sample of The Global Invasive Fungal Infections Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13189&type=smp
What are the top drivers to the rising demand in the invasive fungal infections market?
The rise in the population suffering from human immunodeficiency virus (HIV) is expected to propel the growth of the invasive fungal infection market going forward. HIV (Human Immunodeficiency Virus) infection is a virus that compromises the immune system’s ability to defend against diseases and illnesses. The rising number of individuals with compromised immune systems, such as HIV (Human Immunodeficiency Virus) or AIDS (acquired immunodeficiency syndrome), increases the susceptibility to invasive fungal infections, creating opportunities for manufacturers to develop and supply specialized and more effective antifungal drugs. For instance, in July 2023, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS), the Switzerland-based United Nations program dedicated to addressing the global HIV/AIDS epidemic, the global population living with HIV increased to 39 million in 2022, up 3.17% from 37.7 million in 2020. Furthermore, there were approximately 1.3 million new HIV infections reported in 2022. Therefore, the rise in the population suffering from the human immunodeficiency virus (HIV) will drive the growth of the invasive fungal infection market.
How is the invasive fungal infections market segmented?
The invasive fungal infections market covered in this report is segmented –
1) By Disease Type: Candidemia And Invasive Candidiasis, Intra Abdominal Candidiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Other Disease Type
2) By Drug Type: Polyenes, Triazoles, Echinocandins, Flucytosine, Other Drug Type
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Candidemia And Invasive Candidiasis: Bloodstream Infections, Disseminated Candidiasis
2) By Intra-Abdominal Candidiasis: Peritoneal Candidiasis, Abscess Formation
3) By Cryptococcal Meningitis: Primary Cryptococcal Meningitis, Secondary Cryptococcal Meningitis
4) By Esophageal Candidiasis: Acute Esophageal Candidiasis, Chronic Esophageal Candidiasis
5) By Histoplasmosis Acute Pulmonary: Disseminated Histoplasmosis, Chronic Pulmonary Histoplasmosis
6) By Other Disease Types: Aspergillosis, Mucormycosis, Other Rare Fungal Infections
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report
Who are the top competitors in the invasive fungal infections market?
Major companies operating in the invasive fungal infections market report are Pfizer Inc., Merck And Co. Inc., Bayer AG, Abbott Laboratories, GSK PLC, Gilead Sciences Inc., Siemens Healthineers, Mylan N.V., Astellas Pharma Inc., Quest Diagnostics Incorporated, Sun Pharmaceutical Industries Ltd., BioMérieux SA, BioMarin Pharmaceutical Inc., Xellia Pharmaceuticals, Basilea Pharmaceutica, Cidara Therapeutic Inc., Pulmocide Ltd., NovaBiotics Ltd., F2G Ltd., Giner Inc., Ciron Drugs And Pharmaceuticals Pvt. Ltd., Hexima Limited, Scynexis Inc., Enzon Pharmaceuticals Inc., Matinas BioPharma Holdings Inc., Biosergen AB
What significant trends should we anticipate in the invasive fungal infections market over the forecast period?
Major companies operating in the invasive fungal infection market are focused on innovative products such as Zisavel capsules to enhance treatment efficacy, improve patient outcomes, and increase accessibility for those affected by serious fungal infections. Zisavel capsules are a generic antifungal medication derived from isavuconazole, designed to treat invasive aspergillosis and mucormycosis. These 100 mg capsules aim to provide an affordable alternative for patients, enhancing access to effective treatment. For instance, in October 2023, BDR Pharmaceuticals, an India-based generic and specialty pharmaceutical company, launched a generic antifungal drug, Zisavel Capsules, to treat invasive aspergillosis and mucormycosis. Zisavel is indicated for the treatment of invasive aspergillosis and mucormycosis, both of which are severe fungal infections that can be life-threatening. The introduction of Zisavel aims to make treatment more accessible to patients by significantly lowering costs compared to current options like voriconazole and posaconazole.
Which regional trends are influencing the invasive fungal infections market, and which area dominates the industry?
North America was the largest region in the invasive fungal infections market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the invasive fungal infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Does The Invasive Fungal Infections Market Report 2025 Offer?
The invasive fungal infections market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Invasive fungal infections refer to severe diseases caused by pathogenic fungi that penetrate and spread within the body beyond the point of initial infection. These infections are characterized by the penetration of fungal organisms into deeper layers of tissue, such as the bloodstream, organs, or other body structures. Invasive fungal infection treatment typically includes using antifungal medications and surgical procedures to excise infected tissue in certain instances.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13189
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
